MAT2A-IN-3
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) [1].
Product Specifications
CAS Number
2377493-28-0
UNSPSC
12352005
Target
Somatostatin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mat2a-in-3.html
Solubility
10 mM in DMSO
Smiles
O=C1C(C2=CC=C(OC(F)F)C=C2)=C3N=C(OCC(F)(F)F)N=CC3=CN1C4=CC5=CN(C)N=C5C=C4
Molecular Formula
C24H16F5N5O3
Molecular Weight
517.41
References & Citations
[1]Zenon D. Konteatis, et al. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer. Patent WO2019191470A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HNRNPC, CT (HNRNPC, HNRPC, Heterogeneous nuclear ribonucleoproteins C1/C2) (MaxLight 550) discontinued
ADCK5, NT (Uncharacterized AarF Domain Containing Protein Kinase 5) (HRP)
ADCK5, NT (Uncharacterized AarF Domain Containing Protein Kinase 5) (HRP)
